Credit Suisse Starts Enhabit Home Health & Hospice (EHAB) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EHAB Hot Sheet
Price: $13.80 --0%
Rating Summary:
1 Buy, 10 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
1 Buy, 10 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Credit Suisse analyst A.J. Rice initiates coverage on Enhabit Home Health & Hospice (NYSE: EHAB) with a Neutral rating and a price target of $19.00.
For an analyst ratings summary and ratings history on Enhabit Home Health & Hospice click here. For more ratings news on Enhabit Home Health & Hospice click here.
Shares of Enhabit Home Health & Hospice closed at $15.85 yesterday.
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Jefferies Starts Aura Consolidated Group (AXQ:AU) at Hold
- Freedom Broker Starts Limoneira Company (LMNR) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
